Glucagon as a target for the treatment of Type 2 diabetes.
about
The nucleosome binding protein HMGN3 is expressed in pancreatic alpha-cells and affects plasma glucagon levels in miceA genome-wide siRNA screen to identify modulators of insulin sensitivity and gluconeogenesisPancreatic neuroendocrine tumors in glucagon receptor-deficient mice.Anti-diabetic efficacy and impact on amino acid metabolism of GRA1, a novel small-molecule glucagon receptor antagonistComputational identification of novel natural inhibitors of glucagon receptor for checking type II diabetes mellitus.Interaction of Glucagon G-Protein Coupled Receptor with Known Natural Antidiabetic Compounds: Multiscoring In Silico Approach.Metabolic manifestations of insulin deficiency do not occur without glucagon action.Allosteric modulators of class B G-protein-coupled receptorsPax6 regulates the proglucagon processing enzyme PC2 and its chaperone 7B2.A survey of small molecule glucagon receptor antagonists from recent patents (2006 - 2010).The alpha-cell as target for type 2 diabetes therapy.Structural aspects of gut peptides with therapeutic potential for type 2 diabetes.Selection and characterization of DNA aptamer against glucagon receptor by cell-SELEX.Pharmacokinetic and pharmacodynamic modeling of a monoclonal antibody antagonist of glucagon receptor in male ob/ob miceKinetic modeling of human hepatic glucose metabolism in type 2 diabetes mellitus predicts higher risk of hypoglycemic events in rigorous insulin therapy.Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.TAK-875, a GPR40/FFAR1 agonist, in combination with metformin prevents progression of diabetes and β-cell dysfunction in Zucker diabetic fatty rats.Lipocalin-type prostaglandin D2 synthase reduces glucagon secretion in alpha TC-1 clone 6 cells via the DP1 receptor.Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.D-Fagomine attenuates metabolic alterations induced by a high-energy-dense diet in rats.Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
P2860
Q28593564-694AB0B3-386A-493D-B5E5-9674691F57BBQ28730046-35FC0E92-B926-4451-8F8C-FE4F85609768Q33997146-B6CD4411-1C5F-44F9-B845-8C637C233342Q34490178-BF3A0AE0-4396-4964-84AA-A571E66D5EFFQ34913473-0470484F-1F89-4A0B-B979-D75C825C8DD7Q35868453-368AFFA2-1C82-430B-986D-7095C5189CBCQ36236307-6D2068BC-1D5D-443A-82E1-B284A3D0A33BQ37131132-F7B53FBE-F204-4608-BC36-61E9D94581EDQ37145379-FA9F6986-772B-4C2B-A32E-C2EDA6421BEFQ37884060-83DFA5AD-EEE5-40D3-8AF6-58072C71A42EQ37977335-E3540158-9509-4A7F-90F4-FB068829A223Q38071991-6FFC939D-85F4-4D4A-9CC5-0F2D4451C983Q38287579-1F93CA57-519A-4C24-8D05-DEE0759D0FCDQ38349437-4863E099-E372-427D-8FBF-C9F8C689F833Q41847888-F79B77BF-A832-4D75-83CE-A5011C90CA3FQ42248942-56AD9EEB-943F-4F93-9FEE-AD9F17C08010Q42954535-83804577-4282-4231-882F-949901BC4E3BQ43241195-33C0791F-DED9-4085-98A2-F6A38F9A6702Q46378864-4F7EF864-0D63-49D7-9CDF-A3B33C568D30Q51300585-45CB6A80-4965-48D9-8E34-CE0D44D68A4FQ55032630-C9F5BEB9-B7B0-46D0-BC41-5D4D8A48EF89
P2860
Glucagon as a target for the treatment of Type 2 diabetes.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
Glucagon as a target for the treatment of Type 2 diabetes.
@ast
Glucagon as a target for the treatment of Type 2 diabetes.
@en
type
label
Glucagon as a target for the treatment of Type 2 diabetes.
@ast
Glucagon as a target for the treatment of Type 2 diabetes.
@en
prefLabel
Glucagon as a target for the treatment of Type 2 diabetes.
@ast
Glucagon as a target for the treatment of Type 2 diabetes.
@en
P2093
P2860
P356
P1476
Glucagon as a target for the treatment of Type 2 diabetes.
@en
P2093
Julie S Moyers
Kyle W Sloop
M Dodson Michael
P2860
P304
P356
10.1517/14728222.9.3.593
P407
P577
2005-06-01T00:00:00Z